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Summary Background Sunitinib is an oral multitargeted
tyrosine kinase inhibitor of vascular endothelial growth
factor and platelet-derived growth factor receptors, as well
as of other receptor types. We have performed a feasibility
study to investigate the safety of sunitinib in combination
with pemetrexed for treatment of advanced refractory solid
tumors. Methods Sunitinib was administered once daily on
a continuous daily dosing (CDD) schedule (37.5 mg/day) or
a 2-weeks-on, 1-week-off treatment schedule (50 mg/day,
Schedule 2/1) in combination with pemetrexed at 500 mg/m
2
on day 1 of repeated 21-day cycles. Results Twelve patients
were enrolled in the study: six on the CDD schedule and six
on Schedule 2/1. None of the treated patients experienced a
dose-limiting toxicity. Toxicities were manageable and
similar in type to those observed in monotherapy studies
of sunitinib and pemetrexed. Pharmacokinetic analysis did
not reveal any substantial drug–drug interaction. One
patient with squamous cell lung cancer showed a partial
response and five patients had stable disease. Conclusions
Combination therapy with sunitinib administered on
Schedule 2/1 (50 mg/day) or a CDD schedule (37.5 mg/day)
together with standard-dose pemetrexed (500 mg/m
2)w a s
well tolerated in previously treated patients with advanced
solid tumors.
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Introduction
Progress in the molecular biology of solid tumors has
established the important role of tumor angiogenesis and
the multiple signaling pathways underlying this process in
tumor development [1]. Moreover, antiangiogenic therapy
that targets signaling by the vascular endothelial growth
factor (VEGF) pathway represents a key advance in clinical
oncology [2, 3]. Sunitinib (SUTENT®) is an oral multi-
targeted tyrosine kinase inhibitor of VEGF receptors
(VEGFR1 to VEGFR3), platelet-derived growth factor
receptors (PDGFRα and PDGFRβ), and other receptor
tyrosine kinases [4–6]. It has shown single-agent activity
and acceptable tolerability in phase I/II studies of patients
with a variety of advanced refractory solid tumors [4]. The
clinical benefits observed with sunitinib have resulted in
multinational approval for its use in the treatment of
patients with advanced renal cell carcinoma or imatinib-
resistant or -intolerant gastrointestinal stromal tumors [7, 8].
As targeted agents such as sunitinib enter into clinical
practice, there is interest in assessment of the efficacy and
safety of these agents administered in combination with
chemotherapy in cancer patients, including those with
treatment-refractory tumors. Preclinical studies indicate that
the combination of sunitinib with chemotherapeutic agents
results in increased antitumor activity [9]. One chemothera-
peutic agent tested, pemetrexed, is an antimetabolite that
suppresses cell replication by inhibiting multiple enzymes in
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DOI 10.1007/s10637-010-9565-5the folate pathway and which shows clinical activity against
a broad range of solid tumors, including non-small cell lung
cancer (NSCLC) and mesothelioma [10–12]. The adverse
effects of sunitinib are largely nonoverlapping with those of
pemetrexed, making the latter an appropriate agent, in terms
of safety, for combination with sunitinib. We have now
performed a feasibility study to assess the safety and
tolerability of two dosing schedules of sunitinib (continuous
daily dosing [CDD] schedule and 2 weeks on treatment
f o l l o w e db y1w e e ko f ft r e a t ment [Schedule 2/1]) in
combination with fixed-dose (500 mg/m
2) pemetrexed.
Patients and methods
Study population
Patients with histologically proven advanced solid tumors
and who were 20 years of age or older were enrolled in the
study. Other key inclusion criteria included: prior treatment
with one or more chemotherapy regimens; an Eastern
Cooperative Oncology Group performance status of ≤1;
resolution of acute toxicities resulting from prior therapy;
adequate organ function; and a life expectancy of
≥3 months. Key exclusion criteria included: prior treatment
with pemetrexed or sunitinib or irradiation of≥25% of bone
marrow; hemoptysis (≥5 mL per episode or ≥10 mL/day)
occurring ≤4 weeks before the onset of study treatment;
chemotherapy, surgery, or radiation therapy instituted
<4 weeks before the start of the study (with the exception
of palliative radiotherapy for nontarget lesions); symptom-
atic or uncontrolled brain metastases, spinal cord compres-
sion, carcinomatous meningitis, or leptomeningeal disease;
a history of cardiac disease, cerebrovascular events, or
pulmonary embolism within the 12 months prior to the
onset of study treatment; ongoing cardiac dysrhythmias of
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE) grade≥2, atrial fibrilla-
tion (any grade), or a prolonged QTc interval; hemorrhage
of CTCAE grade 3 within the 4 weeks before the start of
the study treatment; or hypertension that could not be
controlled with standard antihypertensive agents.
Study design and treatment
Thestudywasarandomized,open-labelstudy(NCT00732992)
of sunitinib in combination with pemetrexed in patients
with advanced solid tumors. The primary objective was
assessment of overall safety, including dose-limiting
toxicities (DLTs), for two treatment regimens of sunitinib
plus pemetrexed. Secondary endpoints included plasma
pharmacokinetic evaluations and preliminary antitumor
activity.
Sunitinib was administered orally, once daily, according
to either the CDD schedule or Schedule 2/1. Pemetrexed
(500 mg/m
2) was administered as a 10-min infusion on day
1 of a 21-day cycle. Patients were instructed to take 500 μg
of folate daily, beginning 1 week before day 1 of cycle 1
until study discontinuation. Vitamin B12 (1 g) was injected
intramuscularly 1 week before day 1 of cycle 1 and again
every 9 weeks until study discontinuation. A phase I dose-
escalation trial of sunitinib in combination with pemetrexed
conducted outside of Japan had demonstrated tolerability of
the combination of sunitinib at 37.5 mg (CDD schedule) or
50 mg (Schedule 2/1) with pemetrexed at 500 mg/m
2 [13].
On the basis of these results, we selected the starting doses
of sunitinib in the present study as 37.5 mg for the CDD
schedule cohort and 50 mg for the Schedule 2/1 cohort.
Doses wereinterruptedorreducedifadverseevents ofgrade 3
or 4 were observed. Doses were delayed if a patient did not
meet the following criteria on the first day of each subsequent
cycle: absolute neutrophil count of ≥2,000 cells/μL,
platelet count of ≥100,000 cells/μL, and calculated
creatinine clearance of ≥45 mL/min. Patients were
allowed to undergo a maximum of two dose reductions
of either drug; the minimum dose for pemetrexed was
250 mg/m
2 and that for sunitinib was 25 mg/day.
Treatment was repeated in a 21-day (3-week) cycle until
disease progression, unacceptable toxicity, or withdrawal
of patient consent occurred. DLTs were assessed during
the first treatment cycle and were used to determine
whether the dose or schedule was feasible. They were
defined as drug-related toxicities of grade 3 or 4, including
neutropenia (grade 3 with infection, grade 4 for ≥7d a y s ,
or febrile for >24 h), thrombocytopenia (grade≥3w i t h
b l e e d i n go rg r a d e4f o r≥7 days), lymphopenia accom-
panied by an opportunistic infection, or any nonhemato-
logic toxicity of grade 3 or 4 for ≥7 days. Initially, six
patients were randomized to each dosing schedule (three
patients each). If no more than one of the three patients
experienced a DLT by day 21 of cycle 1, then an additional
six patients (three patients each) were randomized for
treatment at the same dose. If ≥2/3 or ≥2 / 6p a t i e n t so na
schedule experienced a DLT, the dose was reduced and
three additional patients were enrolled.
All patients provided written informed consent. The
study was approved by the institutional review board of
Kinki University Hospital and was performed in accordance
with the International Conference on Harmonization of
Good Clinical Practice guidelines, as well as with applicable
local laws and regulatory requirements.
Study assessments
Safety was assessed according to CTCAE version 3.0. In
patients with measurable disease, objective response was
640 Invest New Drugs (2012) 30:639–646determined according to Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.0 [14].
Pharmacokinetic evaluations
For patients randomized to the CDD schedule, blood
samples were collected on day 1 of cycle 2 (sunitinib,
before as well as 2, 4, 6, 8, 10, and 24 h after dosing;
pemetrexed, before as well as 10 min and 1, 2, 4, 6, 8, 10,
and 24 h after dosing) to evaluate pharmacokinetic
parameters. For patients randomized to Schedule 2/1, blood
samples were collected on day 14 of cycle 1 to determine
the trough level of sunitinib. The plasma concentrations of
sunitinib, its active metabolite (SU12662), and pemetrexed
were measured by validated high-performance liquid
chromatography and tandem mass spectrometry, with the
lower limits of detection being 0.1 ng/mL for sunitinib and
SU12662 and 0.1 μg/mL for pemetrexed. Standard plasma
pharmacokinetic parameters were estimated by noncom-
partmental methods. They included the maximum plasma
concentration (Cmax), plasma predose concentration
(Ctrough), time to Cmax (Tmax), area under the plasma
concentration-time profile from time zero to 24 h after
dosing (AUC0–24), area under the plasma concentration-
time profile from time zero to infinity (AUC0–∞), elimina-
tion half-life (t1/2), oral clearance (CL/F), clearance (CL),
and volume of distribution at steady state (Vss).
Statistical analysis
Given the exploratory nature of the study, all analyses were
descriptive, with no formal statistical test performed on the
data.
Results
Patient characteristics
Twelve patients were enrolled in the study from August to
November2008:sixpatientsfortheCDDscheduleandsixfor
Schedule 2/1. The mostcommon malignancy inthe 12treated
patients was NSCLC (n=9, 75%). All patients received at
least one dose of the study treatment. Patient demographic
and baseline characteristics are summarized in Table 1.
Treatment delivery
A total of 66 cycles of treatment with sunitinib plus
pemetrexed was completed, with a median number of cycles
perpatientoffourforthe CDDscheduleandfiveforSchedule
2/1.All 12patientswereultimatelywithdrawnfromthe study,
the most common reason for which was disease progression
(three patients on the CDD schedule and five patients on
Schedule 2/1). Treatment was withdrawn because of adverse
events in one patient on each schedule (hemoglobin decrease
for the CDD schedule and febrile neutropenia for Schedule
2/1).Sevendosereductionseachfor sunitinibandpemetrexed
were instituted (three for the CDD schedule and four for
Schedule 2/1), mainly as a result of myelosuppression.
Safety
All 12 patients were evaluable for safety analysis. None of
the patients treated on the CDD schedule or Schedule 2/1
experienced a DLT, whereas all individuals experienced at
least one adverse event during the study. The major adverse
events during the entire treatment period are shown in
CDD schedule (n=6) Schedule 2/1 (n=6)
Median (range) age (years) 55.5 (48–69) 66.0 (57–69)
Male/female (n) 6/0 4/2
ECOG performance status 0/1 (n) 2/4 4/2
Primary malignancy (n)
NSCLC 6 3
Pancreatic cancer 0 1
Pancreatic neuroendocrine tumor 0 1
Uterine sarcoma 0 1
Previous therapy (n)
Surgery 2 2
Chemotherapy 6 6
Number of prior regimens (n)
13 5
22 1
≥31 0
Table 1 Patient characteristics
according to dosing schedule
CDD schedule continuous daily
dosing of sunitinib (37.5 mg)
plus pemetrexed (500 mg/m
2)
once every 3 weeks, Schedule 2/1
2-weeks-on and 1-week-off dosing
of sunitinib (50 mg) plus peme-
trexed (500 mg/m
2) once every
3 weeks, ECOG Eastern Coopera-
tive Oncology Group, NSCLC
non-small cell lung cancer
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grade) across both schedules were fatigue (n=11), taste
alteration (n=9), skin discoloration (n=8), anorexia (n=8),
and fever (n=8). Nonhematologic toxicities of grade 3
included diarrhea (n=2) as well as fatigue, proteinuria, and
dehydration (n=1 each) on the CDD schedule, and an
increase in alanine aminotransferase and hypertension (n=1
each) on Schedule 2/1. No nonhematologic toxicities of
grade 4 were observed for either schedule. The most
common hematologic toxicity of grade 3 or 4 was a
decrease in neutrophil number, with six patients (CDD
schedule, n=4; Schedule 2/1, n=2) experiencing this
Adverse event CDD schedule (n=6) Schedule 2/1 (n=6) Total (n=12)
Grade Grade All grades
a
12341234
Nonhematologic
Fatigue 311060001 1
Taste alteration 120060009
Skin discoloration 500030008
Anorexia 310031008
Fever 310031008
AST increased 400011006
Diarrhea 102020005
Stomatitis 110021005
ALT increased 210010105
Hypoalbuminemia 020012005
Hand–foot syndrome 210020005
Vomiting 200020004
Cough 030010004
Rash 210010004
Eyelid edema 100020003
Cheilitis 000030003
Nausea 100011003
Nasopharyngitis 100020003
Proteinuria 001011003
Constipation 100010002
Edema 200000002
Infection 000002002
Dehydration 011000002
Pain-joint 100010002
Headache 200000002
Neuropathy 000020002
Hypertension 010000102
Hypothyroidism
b 000001001
TSH increased
b 010000001
Epistaxis
b 100000001
Hemorrhage
b 010000001
Hematologic
Platelets decreased 312030101 0
Leukocytes decreased 023004101 0
Neutrophils decreased 004101219
Hemoglobin decreased 021011005
Lymphopenia 001000102
Febrile neutropenia
b 000000101
Table 2 Treatment-emergent
(all-causality) adverse events
(NCI CTCAE version 3.0)
occurring with an incidence
of ≥2 cases (or of special
interest) in patients on either
the CDD schedule or
Schedule 2/1
NCI CTCAE National Cancer
Institute Common Terminology
Criteria for Adverse Events,
CDD continuous daily dosing,
AST aspartate aminotransferase,
ALT alanine aminotransferase,
TSH thyroid-stimulating
hormone
aNo adverse events of grade 5
occurred
bAdverse events of special interest
occurring with an incidence
of <2 on either the CDD schedule
or Schedule 2/1
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schedule) at grade 4. Other hematologic toxicities of grade
3 or 4 included a decrease in leukocytes of grade 3 in four
patients (CDD schedule, n=3; Schedule 2/1, n=1), a
decrease in platelets of grade 3 in three patients (CDD
schedule, n=2; Schedule 2/1, n=1), and a decrease in
hemoglobin level of grade 3 in one patient (CDD schedule).
Adverse events considered to be serious occurred in three
patients (CDD schedule, n=2; Schedule 2/1, n=1): one
patient on the CDD schedule had dehydration (grade 2), one
patient on the CDD schedule had infectious enteritis and
dehydration (both of grade 3), and one patient on Schedule
2/1 had pyrexia (grade 2), pneumothorax (grade 1), pleural
effusion (grade 1), and febrile neutropenia (grade 3). There
were no deaths during the study.
Pharmacokinetics
The mean plasma concentration-time profiles and pharma-
cokinetic parameters for sunitinib, its active metabolite
(SU12662), total drug (sunitinib + SU12662), and peme-
trexed for three patients who received the planned treatment
on the CDD schedule are shown in Fig. 1 and Tables 3
and 4. ThemeanCtrough for day 1 of cycle 2 was 45.6 ng/mL
for sunitinib, 25.1 ng/mL for SU12662, and 70.6 ng/mL for
total drug, and each of the corresponding mean plasma
concentration-time profiles showed relatively slow absorp-
tion and elimination, consistent with previous observations
[15]. The pharmacokinetic parameters obtained for sunitinib
(37.5 mg) on the CDD schedule with pemetrexed (500 mg/m
2)
in the present study did not appear to differ substantially from the
dose-normalized parameters previously obtained for single
dosing of sunitinib at 25 or 50 mg [15, 16]. The plasma
concentration of pemetrexed during sunitinib continuous dosing
declined with a fast elimination rate (mean t1/2 was 2.75 h), and
the t1/2,C L ,a n dVss values were similar to those previously
obtained for single dosing of pemetrexed at 500 mg/m
2 [17]. For
Schedule 2/1, the mean Ctrough for day 14 of cycle 1 in six
patients who received the planned treatment was 78.5 ng/mL
Fig. 1 Plasma concentration-time profiles for sunitinib, SU12662,
total drug (sunitinib + SU12662), and pemetrexed on day 1 of cycle 2
for the CDD schedule. Data are means±standard deviation (SD) for
three patients
Table 3 Pharmacokinetic parameters of sunitinib, SU12662, and total drug (sunitinib + SU12662) for the CDD schedule
Parameter Sunitinib SU12662 Total drug
Ctrough (ng/mL) 45.6±11.7 (26) 25.1±5.08 (20) 70.6±13.9 (20)
[41.3] [28.0] [69.3]
Tmax (h) 4 (4–6) 4 (4–4) 4 (4–6)
Cmax (ng/mL) 59.9±10.9 (18) 31.6±5.49 (17) 91.56±14.2 (15)
[59.6] [34.7] [94.3]
AUC0–24 (ng·h/mL) 1,190±247 (21) 675±107 (16) 1,866±269 (14)
[1,161] [665] [1,951]
CL/F (L/h) 32.4±6.65 (20) ND ND
[32.3]
CDD continuous daily dosing, ND no data, SD standard deviation
Data are arithmetic means±SD (coefficient of variation, (%) [median], with the exception of those for Tmax, which are medians (range). Sampling
was performed on day 1 of cycle 2
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total drug. The plasma concentration of sunitinib observed
for both schedules was considered to have achieved a steady
state on the basis of previous results [15]. The Ctrough values
of sunitinib, SU12662, and total drug observed for both the
CDD schedule (sunitinib, 37.5 mg/day) and Schedule 2/1
(sunitinib, 50 mg/day) suggested that the plasma concen-
trations increased in a dose-dependent manner.
Tumor response
Eight of the 12 patients were evaluable for response by
RECIST. A partial response was observed in one patient
with NSCLC on the CDD schedule, whereas five patients
(two on the CDD schedule and three on Schedule 2/1) had
stable disease (Fig. 2a). Most patients showed a decrease in
the size of the target lesion while on the study treatment.
Discussion
Our feasibility study investigated the overall safety of
sunitinib administered on the CDD schedule or Schedule
2/1 in combination with pemetrexed for the treatment of
subjects with advanced refractory solid tumors. Phase I
studies of sunitinib monotherapy have been performed
according to various schedules, including a 3-week cycle
consisting of treatment for 2 weeks followed by a 1-week
rest period (Schedule 2/1), a 4-week cycle comprising
treatment for 2 weeks followed by 2 weeks off treatment
(Schedule 2/2), or a 6-week cycle of treatment for 4 weeks
followed by 2 weeks off treatment (Schedule 4/2) [18, 19].
Daily dosing with sunitinib at 50 mg resulted in a target
Table 4 Pharmacokinetic parameters of pemetrexed for the CDD
schedule
Parameter Value
Tmax (h) 0.167 (0.167–0.167)
Cmax (μg/mL) 1636±30.7 (19) [167]
AUC0–∞ (μg·h/mL) 1916±36.3 (19) [202]
t1/2 (h) 2.7546±0.531 (19) [2.558]
CL (L/h) 4.976±1.38 (28) [4.30]
Vss (L) 10.46±3.13 (30) [10.9]
CDD continuous daily dosing, SD standard deviation
Data are arithmetic means ± SD (coefficient of variation, (%)
[median], with the exception of those for Tmax, which are medians
(range). Sampling was performed on day 1 of cycle 2
Fig. 2 Tumor response. a max-
imum percentage change in the
size of the target lesion in the
eight evaluable patients. PD
progressive disease, PR partial
response,
†stable disease due to
a new bone lesion. b computed
tomography of a solid tumor in
the right lung of a patient indi-
cated by
† in part a at baseline
(left panel) and on day 14 of
cycle 2 for the CDD schedule.
The tumor showed marked
central cavitation after treatment
644 Invest New Drugs (2012) 30:639–646plasma concentration greater than the 50 ng/mL required to
inhibit PDGFR and VEGFR, and DLTs of fatigue, asthenia,
and thrombocytopenia occurred at a dose of 75 mg on all
schedules; a recommended dose of 50 mg was thus
established for Schedules 2/1, 2/2, and 4/2 [4]. Preclinical
and clinical studies showing tumor regrowth during the off-
dosing period suggested that better tumor control might be
achieved with sunitinib on a CDD schedule [20, 21].
Subsequent clinical trials demonstrated that CDD of
sunitinib at 37.5 mg was well tolerated and showed clinical
activity largely similar to that observed for administration
on intermittent schedules, providing flexibility in dosing
schedule [22–24].
Phase I studies have shown that myelosuppression is the
predominant DLT of pemetrexed [25]. We previously found
that the maximum tolerated dose of pemetrexed supple-
mented with folic acid and vitamin B12 was 1,200 mg/m
2,
which was twice the previously determined such dose
(600 mg/m
2) for administration without vitamin supple-
mentation [17, 26]. The results of randomized trials
comparing pemetrexed at 500 mg/m
2 versus 900 mg/m
2
or 1,000 mg/m
2 in patients with recurrent NSCLC showed
that the higher doses did not exhibit a greater clinical
efficacy than the lower dose, thereby establishing the
clinically recommended dose of 500 mg/m
2 for pemetrexed
supplemented with folic acid and vitamin B12 [27, 28].
Given the differences in metabolism and elimination
between sunitinib and pemetrexed, we assessed the safety
of the combination of recommended doses of these drugs.
We initiated treatment with sunitinib at 50 mg/day on
Schedule 2/1 or at 37.5 mg on the CDD schedule together
with pemetrexed at 500 mg/m
2. There were no DLTs in the
12 patients of the present study who received both drugs at
the recommended single-agent doses. Most toxicities were
mild or moderate in extent, and similar in type to those
observed in the monotherapy studies of sunitinib and
pemetrexed. All toxicities of grade 3 or 4 were reversible
and manageable with symptomatic treatment and dose
reduction or interruption. Hypertension is often associated
with treatment with angiogenesis inhibitors, including
sunitinib, but this condition developed in only two patients
in the present study and, in both cases, blood pressure was
controlled with standard antihypertensive therapy. No
patients experienced cardiac abnormalities, including elec-
trocardiogram (ECG) changes or a decline in left ventric-
ular ejection fraction to below the lower limit (50%).
In the present study, the full pharmacokinetic profile was
evaluated at steady state only for the CDD schedule, given
that pharmacokinetic interaction is generally assessed with
high drug exposure. The concomitant administration of
pemetrexed and sunitinib showed no marked effect on the
pharmacokinetics of either drug, compared with previous
single-dosing results. These findings suggest that there was
no substantial pharmacokinetic interaction between suniti-
nib and pemetrexed, consistent with the differences in the
pathways of metabolism and elimination for these drugs.
Sunitinib is primarily metabolized by cytochrome P450-
3A4 (CYP3A4) in hepatic microsomes, whereas peme-
trexed is not metabolized to an appreciable extent, but is
primarily eliminated renally [4, 29]. It is not likely that
sunitinib or its metabolites inhibit the renal elimination of
pemetrexed. In addition, in vitro studies with human liver
microsomes suggested that pemetrexed administration is
not likely to result in clinically relevant inhibition of the
metabolic clearance of drugs metabolized by CYP3A [30].
The trough plasma concentrations for total drug (sunitinib +
SU12662) in both treatment arms of the present study
suggest that sufficient exposure was achieved with regard
to target inhibition, according to the required inhibitory
concentration values.
Although tumor evaluation was not the primary objec-
tive of the present study, and the small sample size
precludes any definitive conclusions regarding treatment
efficacy, antitumor activity data were suggestive of a
potential clinical benefit. It is possible that further peme-
trexed studies might be restricted to patients with non-
squamous NSCLC because of the pemetrexed label
indications [31]. However, the one partial response in the
present study was observed in a patient with squamous
NSCLC; the tumor cavitation apparent in this patient after
study treatment (Fig. 2b) is characteristic of the antitumor
effect of antiangiogenic therapy. Given that sunitinib has
shown promising single-agent activity in patients with
recurrent NSCLC [22, 32], further research is warranted
to determine whether sunitinib might improve the effect of
pemetrexed, not only in nonsquamous NSCLC, but also in
squamous NSCLC.
In conclusion, combination therapy with sunitinib
administered according to Schedule 2/1 (50 mg/day), or a
CDD schedule (37.5 mg/day) together with standard-dose
pemetrexed (500 mg/m
2), was well tolerated in previously
treated patients with advanced solid tumors. In both dosing
schedules, sunitinib exposure remained above the target
plasma concentration in the presence of pemetrexed. Given
that both sunitinib and pemetrexed have shown antitumor
activity as single agents for various types of solid tumors
including NSCLC, sunitinib in combination with peme-
trexed is a viable therapeutic regimen that warrants future
investigation.
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